Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aerogen Inc.
The diabetes market presents competitive, commercial, and regulatory challenges, but its size and breadth spur emerging biotechs to develop an ever-wider range of treatments and technologies.
According to a panel of strategic investors speaking at a recent IN3 meeting, structured deals that can help manage risk for medtech start-ups seeking funding and strategics looking for growth opportunities are on the rise.
Despite the recent downturn in the national economy, Ireland's medical device community is on the verge of a major growth spurt. A lot of the credit goes to strong government support, particularly in the form of Enterprise Ireland, which serves as a major investor in medtech start-ups. Even with such support, Ireland's medtech start-up community faces many of the challenges that any start-up community faces. But the sector has high hopes and great ambitions. The second of a two-part series.
Specializing in controlled breathing technologies for inhaled drug delivery Activaero GMBH is developing a suite of technologies that can efficiently deliver personalized dosing to different targets in the lungs. Activaero is seeking partners with dose-critical or expensive drugs that will benefit from the technology's dose-sparing benefits, or drugs that previously couldn't be delivered using the pulmonary route
- Medical Devices
- Drug Delivery